公开(公告)号：US20240325409A1

公开(公告)日：2024-10-03

申请号：US18587048

申请日：2024-02-26

申请人： Enanta Pharmaceuticals, Inc.

发明人： Sean RAFFERTY ,  Sourav GHORAI ,  Nathaniel Thomas KENTON ,  Peilin XU ,  Samuel BARTLETT ,  Scott MITCHELL ,  Joseph D. PANARESE ,  Yat Sun OR

IPC分类号： A61K31/554 ,  A61K45/06 ,  A61P31/20 ,  C07D513/04

CPC分类号： A61K31/554 ,  A61K45/06 ,  A61P31/20 ,  C07D513/04

摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:




which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20240299304A1

公开(公告)日：2024-09-12

申请号：US18550382

申请日：2022-03-21

申请人： UNIVERSITA DEGLI STUDI DI GENOVA

发明人： Gabriele CAVIGLIOLI ,  Sara BALDASSARI ,  Guendalina ZUCCARI ,  Giorgia AILUNO

IPC分类号： A61K9/24 ,  A61K9/00 ,  A61K9/20 ,  A61K31/155 ,  A61K31/197 ,  A61K31/554

CPC分类号： A61K9/209 ,  A61K9/0065 ,  A61K9/2009 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2095 ,  A61K31/155 ,  A61K31/197 ,  A61K31/554

摘要： A method of preparing a compact bioadhesive, gastroretentive matrix is disclosed. A homogeneous mixture of powders is first prepared which contains an alkylcellulose or an hydroxyalkylcellulose, a water-insoluble, water-swellable cross-linked polycarboxylic polymer and a pH regulator. The mixture of powders is next made into compressed units by direct compression and then heated at a temperature of between 80 and 250° C. for 1-60 minutes. The mixture of powders may also include an active substance. The compressed units thus obtained are characterized by a prolonged release and have a release kinetics of the active substance of substantially zero order in an aqueous solution at pH 1-8.

公开(公告)号：US12053508B2

公开(公告)日：2024-08-06

申请号：US17891835

申请日：2022-08-19

申请人： Hybrid Medical, LLC

发明人： Jeffry Twidwell ,  Joel Buckley ,  Harold Hoium

IPC分类号： A61K38/44 ,  A61K9/00 ,  A61K9/06 ,  A61K9/12 ,  A61K31/277 ,  A61K31/40 ,  A61K31/4422 ,  A61K31/554 ,  A61K35/57 ,  A61K38/21 ,  A61K45/06 ,  A61K47/24 ,  C07D211/90

CPC分类号： A61K38/446 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/12 ,  A61K31/277 ,  A61K31/40 ,  A61K31/4422 ,  A61K31/554 ,  A61K35/57 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  A61K47/24 ,  C07D211/90 ,  C12Y115/01001 ,  A61K38/446 ,  A61K2300/00 ,  A61K31/4422 ,  A61K2300/00 ,  A61K31/554 ,  A61K2300/00 ,  A61K31/277 ,  A61K2300/00 ,  A61K31/40 ,  A61K2300/00 ,  A61K35/57 ,  A61K2300/00 ,  A61K38/212 ,  A61K2300/00

摘要： The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites.

公开(公告)号：US20240133884A1

公开(公告)日：2024-04-25

申请号：US18357065

申请日：2023-07-21

申请人： University of Georgia Research Foundation, Inc.

发明人： Rick Tarleton ,  HuiFeng Shen

IPC分类号： G01N33/569 ,  A61K31/4168 ,  A61K31/554 ,  A61K45/06 ,  A61P33/02 ,  C07K14/44 ,  C07K17/00

CPC分类号： G01N33/56905 ,  A61K31/4168 ,  A61K31/554 ,  A61K45/06 ,  A61P33/02 ,  C07K14/44 ,  C07K17/00 ,  G01N2333/44

摘要： Combinations of Trypanosoma cruzi polypeptides, fusion protein formed therefrom, and compositions and methods of use thereof for improved detection of antibodies against T. cruzi are disclosed. Preferred polypeptide combinations include two or more polypeptides selected from Table 1, or a variant or fragment thereof. In particularly preferred embodiments, the polypeptide combinations include the two polypeptide as paired in Table 2 or Table 3, or variants or fragments thereof. Preferably, the one, or more preferably both, of the polypeptides are antigenic to T. cruzi antibodies. The polypeptide combination can unfused or fused for form fusion proteins. Methods of using the disclosed compositions, including methods of detecting anti-T. cruzi antibodies, diagnosing T. cruzi infections, and monitoring disease status and treatment efficacy are also provided.

公开(公告)号：US20240108729A1

公开(公告)日：2024-04-04

申请号：US18529137

申请日：2023-12-05

申请人： Auson Pharmaceuticals, Inc.

发明人： Peng Hou ,  Enxian Lu ,  Longlong Feng

IPC分类号： A61K47/38 ,  A61K9/06 ,  A61K31/554 ,  A61K47/10 ,  A61K47/12 ,  A61K47/32

CPC分类号： A61K47/38 ,  A61K9/06 ,  A61K31/554 ,  A61K47/10 ,  A61K47/12 ,  A61K47/32

摘要： The present invention provides a pharmaceutical composition of diltiazem hydrochloride. The pharmaceutical composition is preferably a gel and consists of diltiazem hydrochloride and excipients including propylene glycol, benzoic acid, and a gel matrix, which is one of or a mixture of povidone and hydroxypropyl cellulose. Based on percentage by weight, the diltiazem hydrochloride accounts for 1%-5%, the benzoic acid accounts for 0.1%-5.0%, the gel matrix accounts for 5%-10%, and the balance is propylene glycol, with pH maintained at 3.0-4.5. A preparation method is provided accordingly, with simple and readily available raw materials and stable quality.

公开(公告)号：US20240050535A1

公开(公告)日：2024-02-15

申请号：US18126901

申请日：2023-03-27

申请人： Hybrid Medical, LLC

发明人： Jeffry Twidwell ,  Joel Buckley ,  Harold Hoium

IPC分类号： A61K38/44 ,  A61K31/4418 ,  C07D211/90 ,  A61K9/00 ,  A61K47/24 ,  A61K9/06 ,  A61K9/12 ,  A61K31/277 ,  A61K31/40 ,  A61K31/554 ,  A61K31/4422 ,  A61P17/00 ,  A61P19/04 ,  A61K45/06

CPC分类号： A61K38/446 ,  A61K31/4418 ,  C07D211/90 ,  A61K9/0014 ,  A61K47/24 ,  A61K9/06 ,  A61K9/12 ,  A61K31/277 ,  A61K31/40 ,  A61K31/554 ,  A61K31/4422 ,  C12Y115/01001 ,  A61P17/00 ,  A61P19/04 ,  A61K45/06

摘要： The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites.

公开(公告)号：US20230414634A1

公开(公告)日：2023-12-28

申请号：US18031899

申请日：2021-10-18

申请人： GlaxoSmithKline Intellectual Property (No.2) Limited

发明人： Stuart Frederick William KENDRICK ,  Megan M. MCLAUGHLIN

IPC分类号： A61K31/554 ,  A61P17/04

CPC分类号： A61K31/554 ,  A61P17/04

摘要： Methods of treating pruritus, including cholestatic pruritus, particularly cholestatic pruritus in primary biliary cholangitis comprising administration of the compound or a pharmaceutically acceptable salt thereof, are disclosed.

公开(公告)号：US11826378B2

公开(公告)日：2023-11-28

申请号：US17176285

申请日：2021-02-16

申请人： Boehringer Ingelheim Vetmedica GmbH

发明人： Carla Kroh ,  Ingo Ulrich Lang ,  Horst Rose ,  Franziska Roessner ,  Saskia Kley

IPC分类号： A61K31/7034 ,  A61K47/54 ,  A61P9/04 ,  A61K31/138 ,  A61K31/341 ,  A61K31/401 ,  A61K31/4184 ,  A61K31/4422 ,  A61K31/501 ,  A61K31/554 ,  A61K31/585 ,  A61K31/616 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/7056 ,  A61K31/727

CPC分类号： A61K31/7034 ,  A61K31/138 ,  A61K31/341 ,  A61K31/401 ,  A61K31/4184 ,  A61K31/4422 ,  A61K31/501 ,  A61K31/554 ,  A61K31/585 ,  A61K31/616 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/7056 ,  A61K31/727 ,  A61K47/545 ,  A61P9/04

摘要： The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof for the prophylaxis and/or treatment of one or more cardiac diseases in feline animals.

公开(公告)号：US20230364107A1

公开(公告)日：2023-11-16

申请号：US18221784

申请日：2023-07-13

申请人： ARMGO Pharma, Inc.

发明人： Eugene E. MARCANTONIO ,  Mette Uhre ANBY ,  Jérôme BINET

IPC分类号： A61K31/554 ,  A61P21/00 ,  A61K9/28

CPC分类号： A61K31/554 ,  A61P21/00 ,  A61K9/2866 ,  A61K9/2886

摘要： The present disclosure provides a modified-release pharmaceutical composition comprising 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, and a pharmaceutically-acceptable excipient. The present disclosure methods of treating conditions associated with RyRs, including, for example, cardiac disorder or disease, a musculoskeletal disorder or disease, cancer associated muscle weakness, malignant hyperthermia, and diabetes.

公开(公告)号：US11793805B2

公开(公告)日：2023-10-24

申请号：US17505896

申请日：2021-10-20

申请人： Alkermes Pharma Ireland Limited

发明人： Daniel R. Deaver ,  Mark Todtenkopf

IPC分类号： A61K31/485 ,  A61K31/439 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5513 ,  A61K31/554 ,  C07D221/28 ,  C07D405/06 ,  A61K9/20 ,  A61K31/551

CPC分类号： A61K31/485 ,  A61K9/20 ,  A61K31/439 ,  A61K31/496 ,  A61K31/519 ,  A61K31/551 ,  A61K31/554 ,  A61K31/5513 ,  C07D221/28 ,  C07D405/06

摘要： The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.